NTLA:NSD-Intellia Therapeutics Inc. (USD)

EQUITY | Biotechnology | NASDAQ Global Market

Last Closing

USD 20.76

Change

0.00 (0.00)%

Market Cap

USD 0.61B

Volume

1.03M

Analyst Target

USD 30.15
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Intellia Therapeutics Inc is a gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a biological tool known as the CRISPR/Cas9 system.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 102.73B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 96.94B
MRNA Moderna Inc

N/A

USD 38.83B
BNTX BioNTech SE

N/A

USD 22.34B
ARGX argenx NV ADR

N/A

USD 22.28B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 19.03B
GMAB Genmab AS

N/A

USD 18.26B
RPRX Royalty Pharma Plc

N/A

USD 16.73B
BGNE BeiGene Ltd

N/A

USD 16.68B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 15.35B

ETFs Containing NTLA

XDNA 8.89 % 0.00 %

N/A

N/A
MSGR 4.67 % 0.00 %

N/A

N/A
ARKG 0.00 % 0.75 %

N/A

N/A
XSU:CA iShares US Small Cap (CAD.. 0.00 % 0.36 %

N/A

CAD 0.53B
IBBJ 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -31.91% 25% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.91% 25% F 17% F
Trailing 12 Months  
Capital Gain -45.01% 36% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -45.01% 36% F 21% F
Trailing 5 Years  
Capital Gain 27.13% 79% B- 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.13% 79% B- 65% D
Average Annual (5 Year Horizon)  
Capital Gain 99.70% 91% A- 95% A
Dividend Return 99.70% 91% A- 95% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 213.39% 13% F 7% C-
Risk Adjusted Return 46.72% 91% A- 78% C+
Market Capitalization 0.61B 89% A- 80% B-

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 115.00 9% 9%
Price/Book Ratio 2.22 56% 43%
Price / Cash Flow Ratio -5.06 66% 76%
Price/Free Cash Flow Ratio -3.04 65% 72%
Management Effectiveness  
Return on Equity -42.10% 73% 35%
Return on Invested Capital -40.74% 67% 26%
Return on Assets -22.83% 68% 23%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector